BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The European School of Multimodality Imaging & Therapy (ESMIT)
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251204T080000
DTEND;TZID=Europe/Vienna:20251205T170000
DTSTAMP:20260421T173024
CREATED:20241017T084515Z
LAST-MODIFIED:20250624T123657Z
UID:1968-1764835200-1764954000@esmit.eanm.org
SUMMARY:Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6
DESCRIPTION:Breast cancer is the most relevant cancer in women worldwide. It is the second most frequently diagnosed cancer (after lung cancer) and the first leading cause of cancer-related death in women\, being the fourth globally regardless of gender. By 2040\, breast cancer is predicted to increase to over 3 million new cases and 1 million deaths per year. \n\n\n\nStaging patients with breast cancer is challenging due to its heterogeneous nature and presentation. Imaging is of utmost importance in all clinical settings\, particularly\, in staging\, assessing therapy response\, and detecting recurrence. Despite the well-stablished usefulness of radiologic modalities\, Nuclear Medicine has demonstrated an important role to play in breast cancer\, which has been increasingly supported by strong scientific evidence. Considering the patient’s long survival\, the benefits of assessing active tumour in an accurate way\, gain major importance in these patient’s care. \n\n\n\nThe recent equipment and radiopharmaceutical developments have opened the path to improve tumour characterization through several imaging possibilities. Currently\, the challenge is to use the correct combination of equipment and tracer at the right time. Furthermore\, homogenize imaging and clinical procedures is becoming even more important. \n\n\n\nDuring this course\, the highlights from the consensus reached during the multidisciplinary EANM Focus Meeting 6 about Nuclear Medicine diagnostics and therapeutics possibilities will be comprehensively presented and discussed in a close way between the faculty and attendees. \n\n\n\n\n\n\n\nRegister nowRegistration is now open\, save yourself a seat! Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo understand breast cancer as a heterogeneous disease\, its characteristics and evolution;\n\n\n\nTo define the role of nuclear medicine techniques in different clinical settings (initial staging\, assessing therapy response\, and detecting recurrence);\n\n\n\nTo know the potential usefulness of PET tracers beyond FDG in each breast cancer subtype and use of the evolving PET technology & equipment;\n\n\n\nTo discuss future diagnostic and treatment approaches with radiopharmaceuticals.\n\n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear Medicine physicians\, Radiologists\, Medical Oncologists\, Radiation Oncologists\, Medical students\, Residents\, Nurses\, Nuclear Medicine technologists and Radiographers. \n\n\n\n \n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSofia VazSpeakerLisbon\, Portugal \n\n\n\n\n\nThiemo van NijnattenSpeakerMaastricht\, Netherlands \n\n\n\n\n\nPhilipp BackhausSpeakerMünster\, Germany \n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/nuclear-medicine-in-breast-cancer-based-on-focus-meeting-6/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Clinical Nuclear Medicine,Onsite Course
END:VEVENT
END:VCALENDAR